Geode Capital Management’s Entrada Therapeutics TRDA Stock Holding History
Bought
Maintained
Sold
Other funds holding TRDA
BBA
Geode Capital Management's TRDA Position: Q3 2026 in Review
Geode Capital Management reduced its Entrada Therapeutics (TRDA) stake by 1.2% in Q3 2026, selling an estimated $62K and leaving 708,490 shares worth $4.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2911.
Geode Capital Management first reported a position in TRDA in Q4 2021 and has held it in 20 quarters since. The position peaked at $9.9M in Q4 2024. 132 funds tracked by Wall St. Rank hold TRDA as of Q3 2026.
- Geode Capital Management held 708,490 shares of Entrada Therapeutics worth $4.5M as of Q3 2026.
- Geode Capital Management sold 8,940 Entrada Therapeutics shares in Q3 2026, an estimated $62K.
- Entrada Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q3 2026, its #2911 holding.
- Geode Capital Management first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 20 quarters since.
- Geode Capital Management's Entrada Therapeutics position peaked at $9.9M in Q4 2024.
- 132 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2026.
Based on Geode Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.